Respiratory Acidosis: Low Arterial Blood pH with Increased Arterial pCO2 and Arterial H2CO3- Increased
Neuromuscular disorders that decrease breathing, as produced by brain stem injury, myasthenia gravis, and poliomyelitis
If sufficiently severe, multiple non-neuromuscular causes of impaired ventilation, perfusion, or gas diffusion produced by embolism, infection, selected cancers, asthma, bronchitis, and emphysema.
Suggested Additional Lab Testing
Serial blood gases to assess arterial pH, arterial pco2 and arterial h2co3 are important to determine the severity and progression of disorders producing respiratory acidosis.
Any neuromuscular disorder or non-neuromuscular disorder leading to respiratory acidosis must be specifically identified from clinical signs and symptoms and other diagnostic tests.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Lenalidomide Induces Immunity, Produces Clinical Response in CLL
- Comorbidities Signal Worse Outcomes in CLL After Targeted Treatment
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia